{"filings":[{"id":591796,"accession_number":"0001731122-26-000781","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-22T12:15:26+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice received May 20, 2026 due to late Form 10-Q for quarter ended March 31, 2026.","Company must submit a compliance plan by July 20, 2026 to regain listing compliance.","If plan is accepted, Nasdaq may grant an exception until November 16, 2026 to file.","No immediate effect on AVXL listing; stock continues trading on Nasdaq Global Select.","Anavex states it is working to complete and file the 10-Q and submit the compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471116,"accession_number":"0001731122-26-000744","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-15T20:15:25+00:00","items":["5.02"],"status":"ready","headline":"Anavex COO Felix Lauscher departs May 11 amid reorganization after interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Felix Lauscher, COO since March 1, 2026, left Anavex on May 11, 2026.","Departure part of broader reorganization after appointing Dr. Terrie Kellmeyer as Interim CEO.","Lauscher had $264K annual base salary; received prorated pay for service period.","Of 50,000 stock options granted, 45,833 forfeited; 4,167 vested at $4.69/share exercisable until Aug 9, 2026.","Offered two weeks' additional compensation at base salary in exchange for general release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92033,"accession_number":"0001731122-26-000678","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.","Terrie Kellmeyer appointed Interim CEO effective May 4, 2026; former SVP Clinical Development at Anavex.","Kellmeyer's compensation: $500k base salary, 30% bonus, $150k signing bonus, 200k stock options pending.","Company expects to file Form 12b-25 to extend deadline for Q2 2026 10-Q (quarter ended March 31, 2026).","Conference call to discuss Q2 2026 financial results and filing to be scheduled later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102518,"accession_number":"0001731122-26-000482","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex withdraws EU marketing application for blarcamesine for early Alzheimer's after CHMP negative feedback","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.","Decision follows CHMP indication it would not issue a positive opinion at this time.","Company will gather additional data and conduct further analyses to address CHMP concerns.","Anavex had submitted application after EMA SME Office encouragement in October 2023.","CEO affirms commitment to advancing oral therapies for early Alzheimer's and continuing regulatory engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102517,"accession_number":"0001731122-26-000305","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Anavex appoints Dr. Axel Paeger to Board of Directors effective Feb 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Paeger appointed to fill a vacancy on the board, effective February 23, 2026.","Board determined Paeger is independent under Exchange Act and Nasdaq rules.","Paeger is CEO of AMEOS Group, Europe's leading healthcare provider with 85 hospitals and 19,300 employees.","No arrangements or transactions requiring disclosure under Item 404(a) between Paeger and Anavex.","Paeger brings 30+ years of healthcare leadership; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102516,"accession_number":"0001731122-26-000193","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.","Cash & equivalents $131.7M (up from $102.6M); company expects cash runway >3 years.","EU CHMP issued negative opinion for blarcamesine in early Alzheimer's; Anavex requested EMA re-examination (Dec 2025).","FDA Type C meeting in Jan 2026 showed interest; company will submit additional Phase IIb/III data for potential NDA.","Appointed Wolfgang Liedtke as SVP Global Head of Neurology; joined ACCESS-AD initiative."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118784,"accession_number":"0001731122-25-001591","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.","Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.","CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.","Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.","Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118783,"accession_number":"0001731122-25-001536","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.","Company intends to request re-examination upon formal adoption, including providing relevant biomarker data.","FDA advised Anavex to request a meeting to discuss Alzheimer's clinical trial results.","No change to ongoing FDA review process; company remains in dialogue with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135316,"accession_number":"0001731122-25-001033","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Anavex Life Sciences enters $150M at-the-market equity facility with TD Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with TD Securities (USA) LLC for ATM offering of up to $150M in common stock.","Shares sold under shelf registration statement filed July 14, 2025, effective July 23, 2025.","Sales agent commission up to 3.0% of gross proceeds; company not obligated to sell any shares.","Sales may be conducted on Nasdaq or in negotiated transactions; offering can be suspended by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135315,"accession_number":"0001731122-25-000935","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anavex extends CEO Missling's term to 2028 with $800k salary; PFO receives indefinite term and increased severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Christopher Missling's employment term extended through July 5, 2028, with base salary $800,000 and target cash bonus of 20% of salary.","PFO Sandra Boenisch's employment made indefinite; base salary set at CAD $279,840 with 20% target bonus.","Boenisch's severance upon termination without cause increased from 6 to 12 months of base salary.","Both amendments effective July 3, 2025; Missling's annual equity grant remains at Compensation Committee's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152280,"accession_number":"0001731122-25-000878","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anavex shareholders OK plan amendment to add 4M shares, enforce one-year vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2022 Omnibus Incentive Plan increases authorized shares from 10M to 14M.","New awards subject to minimum one-year vesting; exceptions for substitutions, cash awards, 5% pool, change in control, death/disability.","Liberal share recycling prohibited: shares used for exercise price or tax withholding cannot be re-added to plan reserve.","All six director nominees elected (Missling, Ma, van der Velden, Skarpelos, Thomas, Donhauser) with >85% of votes cast.","Ratification of Grant Thornton LLP as independent auditor received 49.6M for vs 1.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204605,"accession_number":"0001731122-24-001160","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Anavex terminates at-the-market equity offering agreement with Cantor Fitzgerald and SVB Securities","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Terminated the Amended and Restated Sales Agreement dated May 1, 2020 effective July 24, 2024.","Agreement allowed sale of common stock (AVXL) at company's discretion through Sales Agents.","No penalties associated with the termination.","Sales Agents were Cantor Fitzgerald & Co. and SVB Securities LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221416,"accession_number":"0001731122-24-001003","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anavex Life Sciences Announces Results of 2024 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected six directors including Christopher Missling, PhD, with 30,256,642 for and 3,637,351 against, plus 22,413,981 broker non-votes.","Ratified Grant Thornton LLP as independent auditor with 54,408,426 for, 1,275,036 against, and 624,512 abstentions.","Approved non-binding advisory resolution on executive compensation (say-on-pay) with 28,406,111 for, 4,728,255 against.","Shareholder proposal on golden parachutes failed with 18,454,499 against, 13,199,210 for, and 2,240,280 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221415,"accession_number":"0001731122-24-000758","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.","Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.","R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.","Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.","First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}